Medial frontal cortex perfusion abnormalities as evaluated by positron emission tomography in women with climacteric symptoms

Menopause

Volumn 13, Issue 6, 2006, Pages 891-901

  Abe, Tetsuro ^a   Bereczki, Daniel ^b   Takahashi, Yasuo ^c   Tashiro, Manabu ^d   Iwata, Ren ^d   Itoh, Masatoshi ^d  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c TOHOKU GAKUIN UNIVERSITY   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

Author keywords

Climacteric symptoms; Menopause; Positron emission tomography; Regional cerebral blood flow

Indexed keywords

CARBON DIOXIDE;

ADULT; AGE DISTRIBUTION; ARTHRALGIA; ARTICLE; BRAIN BLOOD FLOW; CARBON DIOXIDE BREATHING; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FATIGUE; FEMALE; FORMICATION; FRONTAL CORTEX; HEADACHE; HEART PALPITATION; HOSPITAL PERSONNEL; HUMAN; INSOMNIA; JAPAN; MELANCHOLIA; MENOPAUSAL SYNDROME; MENOPAUSE; MYALGIA; NERVOUSNESS; NEUROIMAGING; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; SELF CONCEPT; STATISTICAL ANALYSIS; VASOMOTOR DISORDER; VERTIGO;

CEREBROVASCULAR CIRCULATION; FEMALE; FRONTAL LOBE; HUMANS; JAPAN; MENOPAUSE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 33751050177     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000227852.82303.d7     Document Type: Article

References (72)

1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Geneva, Switzerland: World Health Organization, 1992.
2. Kupperman HS, Wetchler BB, Blatt MHG. Contemporary therapy of the menopausal syndrome. JAMA 1959;171:1627-1637.
3. Avis NE, Stellato R, Crawford S, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ethnic groups. Soc Sci Med 2001;52:345-356.
4. Freedman RR. Physiology of hot flashes. Am J Hum Biol 2001;13:463-464.
5. Vanwesenbeeck I, Vennix P, van de Wiel H. 'Menopausal symptoms': associations with menopausal status and psychosocial factors. J Psychosom Obstet Gynaecol 2001;22:149-158.
6. Freedman RR, Blacker CM. Estrogen raises the sweating threshold in postmenopausal women with hot flashes. Fertil Steril 2002;77:487-490.
7. Zhao G, Wang L, Yan R, Donenrstein L. Menopausal symptoms: experience of Chinese women. Climacteric 2000;3:135-144.
8. Hardy R, Kuh D. Change in psychological and vasomotor symptom reporting during the menopause. Soc Sci Med 2002;55:1975-1988.
9. Joffe H, Hall JE, Soares CN, et al. Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 2002;9:392-398.
10. Calvaresi E, Bryan J. Symptom experience in Australian men and women in midlife. Maturitas 2003;44:225-236.
11. Joffe H, Soares CN, Cohen LS. Assessment and treatment of hot flushes and menopausal mood disturbance. Psychiatr Clin North Am 2003;26:563-580.
12. Ho SC, Chan SG, Yip YB, Cheng A, Yi Q, Chan C. Menopausal symptoms and symptom clustering in Chinese women. Maturitas 1999;33:219-227.
13. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. The Menopause Rating Scale (MRS II): methodological standardization in the German population [in German]. Zentralbl Gynakol 2000;122:280-286.
14. Schneider HP, Rosemeier HP, Schnitker J, Gerbsch S, Turck R. Application and factor analysis of the menopause rating scale [MRS] in a post-marketing surveillance study of Climen. Maturitas 2000;37:113-124.
15. Barentsen R, van de Weijer PH, van Gend S, Foekema H. Climacteric symptoms in a representative Dutch population sample as measured with the Greene Climacteric Scale. Maturitas 2001;38:123-128.
16. Deleted in proof.
17. Becker D, Lomranz J, Pines A. Psychological distress around menopause. Psychosomatics 2001;42:252-257.
18. Freeman EW, Sammel MD, Liu L, Martin P. Psychometric properties of a menopausal symptom list. Menopause 2003;10:258-265.
19. Anderson D, Yoshizawa T, Gollschewski S, Atogami F, Courtney M. Menopause in Australia and Japan: effects of country of residence on menopausal status and menopausal symptoms. Climacteric 2004;7:167-174.
20. Freeman EW, Sammel MD, Rinaudo PJ, Sheng L. Premenopausal syndrome as a predictor of menopausal symptoms. Obstet Gynecol 2004;103:960-966.
21. Gold EB, Block G, Crawford S, et al. Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation. Am J Epidemiol 2004;159:1189-1199.
22. Li C, Samsioe G, Borgfeldt C, Lidfeldt J, Agardh CD, Nerdrand C. Menopause-related symptoms: what are the background factors? A prospective population-based cohort study of Swedish women (The Women's Health in Lund Area study). Am J Obstet Gynecol 2003;189:1646-1653.
23. Bromberger JT, Harlow S, Avis N, Kravitz HM, Cordal A. Racial/ethnic differences in the prevalence of depressive symptoms among middle-aged women: The Study of Women's Health Across the Nation (SWAN). Am J Public Health 2004;94:1378-1385.
24. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473.
25. Soares CN, Cohen LS. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J 2001;119:78-83.
26. Brown WJ, Mishra GD, Dobson A. Changes in physical symptoms during the menopause transition. Int J Behav Med 2002;9:63-67.
27. Woods NF, Mariella A, Mitchell ES. Patterns of depressed mood across the menopausal-transition: approaches to studying patterns in longitudinal data. Acta Obstet Gynecol Scand 2002;81:623-632.
28. Stoppe G, Doren M. Critical appraisal of effects of estrogen replacement therapy on symptoms of depressed mood. Arch Women Ment Health 2002;5:39-47.
29. Bosworth HB, Bastian LA, Kuchibhartla MN, et al. Depressive symptoms, menopausal status, and climacteric symptoms in women at midlife. Psychosom Med 2001;63:603-608.
30. Freeman EW, Sammel MD, Liu L, Garcia CR, Nelson DB, Hollander L. Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry 2004;61:62-70.
31. Binfa L, Castelo-Branco C, Blumel JE, et al. Influence of psychosocial factors on climacteric symptoms. Maturitas 2004;48:425-431.
32. Bromberger JT, Meyer PM, Kravitz HM, et al. Psychologic distress and natural menopause: a multiethnic community study. Am J Public Health 2001;91:1435-1442.
33. Maartens LW, Knottnerus JA, Pop VJ. Menopausal transition and increased depressive symptomatology: a community based prospective study. Maturitas 2002;42:195-200.
34. Illanes E, Bustos L, Lagos S, Navaro N, Munoz S. Associated factors to depressive symptoms and somatic symptoms in climacteric women in the city of Temuco [in Spanish]. Rev Med Chil 2002;130:885-891.
35. Dell DL, Stewart DE. Menopause and mood. Is depression linked with hormone changes? Postgrad Med 2000;108:34-36, 39-43.
36. Richardson TA, Robinson RD. Menopause and depression: a review of psychologic function and sex steroid neurobiology during the menopause. Prim Care Update Ob/Gyns 2000;7:215-223.
37. Avis NE, Crawford S, Stellato R, Longcope C. Longitudinal study of hormone levels and depression among women transitioning through menopause. Climacteric 2001;4:243-249.
38. Banger M. Affective syndrome during perimenopause. Maturitas 2002;41:S13-S18.
39. Rajewska J, Rybakowski JK. Depression in premenopausal women: gonadal hormones and serotonergic system assessed by D-fenfluramine challenge test. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:705-709.
40. Bromberger JT, Assmann SF, Avis NE, Schocken M, Fravitz HM, Cordal A. Persistent mood symptoms in a multiethnic community cohort of pre- and perimenopausal women. Am J Epidemiol 2003;158:347-356.
41. Birkhauser M. Depression, menopause and estrogens: is there a correlation? Maturitas 2002;41(suppl 1):S3-S8.
42. Kugaya A, Epperson CN, Zoghbi S, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women. Am J Psychiatry 2003;160:1522-1524.
43. Editorial Board (Maturitas). Instructions to authors. Maturitas 1983;5:59-66.
44. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
45. Zung WWK, Richards CB, Gables C, Short MJ. Self-rating depression scale in an outpatient clinic. Arch Gen Psychiatry 1965;13:508-515.
46. Fukuda K, Kobayashi S. A study on a self-rating depression scale [in Japanese]. Seishin Shinkeigaku Zasshi 1973;75:673-679.
47. Abe T, Moritsuka T, eds. KKSI [Kupperman Kohnenki Shogai Index] (Kuppahman-Kohnenki-Shohgai-Shisuh, Abe-henpoh) Shiyoh-tebiki [originally published in Japanese]. Kyoto, Japan: Sankyoboh, 1996.
48. Kasuga M, Makita K, Ishitani K, et al. Relation between climacteric symptoms and ovarian hypofunction in middle-aged and older Japanese women. Menopause 2004;11:631-638.
49. Lammertsma AA, Cunningham VJ, Deiber MP, et al. Combination of dynamic and integral methods for generating reproducible functional CBF images. J Cereb Blood Flow Metab 1990;10:675-686.
50. Iida H, Kanno I, Miura S, Murakami M, Takahashi K, Uemura K. A determination of the regional brain/blood partition coefficient of water using dynamic positron emission tomography. J Cereb Blood Flow Metab 1989;9:874-885.
51. Watanuki S, Ishii K, Orihara H, Fukuda F. Status of multi-ring high-resolution positron emission tomography system PT931. CYRIC Annu Rep 1986:244-250.
52. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frackowwiak RSJ. Spatial registration and normalization of images. Hum Brain Mapp 1995;2:165-189.
53. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996;4:223-235.
54. Talairach J, Tournoux PS. Co-planar Stereotaxic Atlas of the Human Brain. 3-Dimensional Proportional System: An Approach to Cerebral Imaging. Stuttgart, Germany: Thieme, 1998.
55. Worsley KJ, Evans AC, Marrett S, Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 1992;12:900-918.
56. Worsley KJ, Marrett S, Neelin P, Vandal SC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Mapp 1996;4:58-73.
57. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapp 1994;1:214-220.
58. Senda M, Ishii K, Oda K, et al. Influence of ANOVA design and anatomical standardization on statistical mapping for PET activation. Neuroimage 1998;8:283-301.
59. Poline JB, Vandenberghe R, Holmes AP, Friston KJ, Frackowiak RSJ. Reproducibility of PET activation studies: lessons from a multi-center European experiment. EU concerted action on functional imaging. Neuroimage 1996;4:34-54.
60. Drevets WC, Price JL, Simpson JR Jr, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997;386:824-827.
61. Dolan RJ, Bench CJ, Brown RG, Scott IC, Friston KJ, Frackowiak RSJ. Regional cerebral blood flow abnormalities in depressed patients with cognitive impairment. J Neurol Neurosurg Psychiatry 1992;55:768-773.
62. Charmichael ST, Prince JL. Limbic connection of the orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol 1995;363:615-641.
63. Bechare A, Tranel D, Damasio SR. Failure to respond autonomically to anticipated future outcomes following damage to the prefrontal cortex. Cereb Cortex 1996;6:215-225.
64. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association, 1995.
65. Moses EL, Drevets WC, Smith G, et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol Psychiatry 2000;48:854-860.
66. Yamasue H, Kasai K, Iwanami A, et al. Voxel-based analysis of MRI reveals anterior cingulated gray-matter volume reduction in posttraumatic stress disorder due to terrorism. Proc Natl Acad Sci USA 2003;100:9039-9043.
67. Fuster JM, ed. The Prefrontal Cortex. Anatomy, Physiology, and Neuropsychology of the Frontal Lobe, 2nd ed. New York, NY: Raven Press, 1988.
68. Berman KF, Schmidt PJ, Rubinow DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids: a positron-emission tomography study in women. Proc Natl Acad Sci USA 1997;94:8836-8841.
69. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen's effect on cognition. Psychoneuroendocrinology 2001;26:577-590.
70. Felthous AR, Robinson DB. Oral contraceptive medication in prevention of psychotic exacerbations associated with phases of the menstrual cycle. J Prev Psychiatry 1981;1:5-14.
71. Fettes I. Migraine in the menopause. Neurology 1999;53(suppl 1):S29-S33.
72. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-878.